



11th Vaccine Congress

17-20 September 2017 • Paradise Point, San Diego, CA, USA



11th Vaccine Congress | Poster Program

POSTER PROGRAM

Posters Session I

Sunday, 17 September 2017 at 17:00-18:30

[P1.01]	Rubella - Epidemiological perspective in India A. Chauhan*, M. Singh, S. Garg, <i>Maulana Azad Medical College, India</i>
[P1.03]	MicA, a small noncoding RNA, from <i>E. coli</i> induces production of OmpC-enriched outer membrane vesicles that protect against <i>Salmonella</i> challenge K.S. Kim, <i>Pusan National University, Republic of Korea</i>
[P1.04]	A novel therapeutic vaccine against multi-drug resistant tuberculosis in the preclinical study and clinical trial. M. Okada* ¹ , K. Tomono ² , T. Nakajima ³ , Y. Kaneda ² , Y. Inoue ¹ , K. Tsuyuguchi ¹ , S. Shoji ⁴ , A. Mikami ⁵ , T. Saito ⁶ , T. Matsumoto ⁷ , ¹ <i>National Hospital Organization Kinki-chuo Chest Medical Center, Japan</i> , ² <i>Osaka University, Japan</i> , ³ <i>Genomidea Co, Japan</i> , ⁴ <i>NHO Tokyo Hospital, Japan</i> , ⁵ <i>National Center for Global Health and Medicine, Japan</i> , ⁶ <i>NHO Ibaraki-higashi Hospital, Japan</i> , ⁷ <i>Osaka Hospital anti-tuberculosis association, Japan</i>
[P1.05]	Development of the decision aid for aTd vaccine for the sri lankan parents/guardians P. Liyanage* ¹ , C.S.E. Goonewardena ¹ , P. Palihawadana ¹ , ¹ <i>Ministry of Health, Sri Lanka</i> , ² <i>University of Sri Jayawardenapura, Sri Lanka</i>
[P1.06]	Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology Y.T. Yang ¹ , Y.H. Chow ¹ , K.N. Hsiao ¹ , K.C. Hu ¹ , J.R. Chiang ² , S.C. Wu ³ , P. Chong ¹ , C.C. Liu* ¹ , ¹ <i>National Health Research Institutes, Taiwan</i> , ² <i>Centers for Disease Control, Taiwan</i> , ³ <i>National Tsing Hua University, Taiwan</i>
[P1.07]	A novel vaccine construct inactivated by a regulated autolysis system and expressing the B subunit of Shiga toxin 2e efficiently elicits immune responses and confers protection against virulent Stx2e-producing <i>Escherichia coli</i> J.H. Lee, <i>Chonbuk National University, Republic of Korea</i>
[P1.08]	Homologous prime-boost immunization with live attenuated <i>Salmonella enterica</i> serovar Senftenberg and its preventive efficacy against experimental challenge with various strains of <i>S. Senftenberg</i> J.H. Lee, <i>Chonbuk National University, Republic of Korea</i>
[P1.09]	Immunization with <i>Salmonella Enteritidis</i> secreting mucosal adjuvant labile toxin confers protection against wild type challenge via augmentation of CD3+CD4+ T-cell proliferation and enhancement of IFNγ, IL-6 and IL-10 expressions in chicken J.H. Lee, <i>Chonbuk National University, Republic of Korea</i>
[P1.10]	Overcoming Freeze-Thaw Agglomeration of a Meningococcal vaccine C.D. Mensch*, H.B. Davis, J.T. Blue, <i>Merck, USA</i>
[P1.11]	Immunization services: involvement of community pharmacies in Lagos state, Nigeria O.T. Fowowe* ^{1,2} , B.O. Aina ^{1,2} , ¹ <i>University Of Lagos, Nigeria</i> , ² <i>Pharmaceutical society of Nigeria, Nigeria</i>
[P1.12]	Stabilization and maintenance of viral vector functionality by means of the amino acid-based SPS[®] formulation technology platform M. Scholz*, K. Kemter, <i>LEUKOCARE AG, Germany</i>
[P1.13]	Self-assembled photosensitizer-antigen conjugates for cancer immunotherapy F.Q. Cao, M.M. Yan, G.L. Ma*, <i>Peking Union Medical College & Chinese Academy of Medical Sciences, China</i>
[P1.14]	Comparability of vaccine safety outcomes during the ICD-9 and ICD-10 transition in Kaiser Permanente Southern California L. Qian* ¹ , L.S. Sy ¹ , D. Ly ¹ , E. Weintraub ² , S. Glenn ¹ , S.J. Jacobsen ¹ , ¹ <i>Kaiser Permanente Southern California, USA</i> , ² <i>Centers for Disease Control and Prevention, USA</i>
[P1.15]	Cost effectiveness of a targeted age-based West Nile virus vaccination program M.B. Shankar, J.E. Staples, M.I. Meltzer, M. Fischer, R. Chen*, <i>Centers for Disease Control and Prevention, USA</i>
[P1.16]	Preclinical assessment of virus-like particle-associated pre- and post-fusion forms of respiratory syncytial virus F protein in maternal vaccination J.C.G. Blanco* ¹ , L.M. Pletneva ¹ , L. McGinness ² , R.O. Oue ¹ , M.C. Patel ¹ , M.S. Boukhvalova ¹ , T.G. Morrison ² ,



11th Vaccine Congress

17-20 September 2017 • Paradise Point, San Diego, CA, USA



11th Vaccine Congress | Poster Program

	¹ <i>Sigmovir Biosystems Inc, USA</i> , ² <i>University of Massachusetts Medical School, USA</i>
[P1.17]	Brief education to promote maternal influenza vaccine uptake: a randomized controlled trial V.W.Y. Wong ¹ , D.Y.T. Fong ¹ , K.Y.W. Lok ¹ , J.Y.H. Wong ¹ , C. Sing ^{1,2} , A.Y.Y. Choi ^{1,3} , C.Y.S. Yuen ¹ , M. Tarrant ^{*1,4} , ¹ <i>University of Hong Kong, Hong Kong</i> , ² <i>Kwong Wah Hospital, Hong Kong</i> , ³ <i>Queen Mary Hospital, Hong Kong</i> , ⁴ <i>University of British Columbia, Canada</i>
[P1.18]	Seroprevalence of antibodies against leptospire in clinically healthy horses in Czech Republic J. Nepereny ^{*1} , V. Vrzal ¹ , F. Trem ^{1,2} , ¹ <i>Bioveta, a. s., Czech Republic</i> , ² <i>University of Veterinary and Pharmaceutical Sciences, Czech Republic</i>
[P1.19]	Biophysical formulation screens of recombinant DEN 80E from dengue virus strains using 96-well plates P.L. Ahl [*] , S. McClure, J. Blue, <i>Merck Research Labs, USA</i>
[P1.20]	Next generation live attenuated anthrax vaccines exhibiting mutations in virulence determinants: efficacy evaluation in guinea pigs, rabbits and non-human primates T. Chitlaru [*] , M. Israeli, U. Elia, S. Rotem, E. Bar-Haim, A. Shafferman, O. Cohen, <i>Israel Institute for Biological Research, Israel</i>
[P1.21]	Evaluation of cell-mediated immunity against varicella zoster virus in guinea pigs K. Yoo [*] , H. Nam, E. Kim, <i>MOGAM institute for biomedical research, Republic of Korea</i>
[P1.22]	Development of canine live attenuated influenza vaccines L. Rodriguez ^{*1} , A. Nogales ¹ , E. C. Reilly ¹ , D. J. Topham ¹ , P. R. Murcia ² , C. R. Parrish ³ , L. Martinez-Sobrido ¹ , ¹ <i>University of Rochester, USA</i> , ² <i>MRC-University of Glasgow Centre for Virus Research, UK</i> , ³ <i>Cornell University, USA</i>
[P1.23]	Development of an equine influenza virus live attenuated vaccine L. Rodriguez ^{*1} , A. Nogales ¹ , T. Chambers ² , P. R. Murcia ³ , L. Martinez-Sobrido ¹ , ¹ <i>University of Rochester, USA</i> , ² <i>Gluck Equine Research Center, University of Kentucky, USA</i> , ³ <i>MRC-University of Glasgow Centre for Virus Research, UK</i>
[P1.25]	Results of a Phase 1a study of M2SR influenza vaccine in healthy adults P. Bilsel [*] , R. Herber, P. Radspinner, <i>FluGen, USA</i>
[P1.26]	Comparison of signal sequences that enhance antibody responses in DNA encoding the bovine viral diarrhea virus E2 protein I. Naito ^{1,2} , S. Nakayama ¹ , Y. Chiba ^{*1} , K. Kameyama ³ , T. Tsuboi ³ , T. Kokuho ³ , M. Kaneda ² , H. Hikono ^{1,2} , K. Murakami ^{1,2} , ¹ <i>Iwate University, Japan</i> , ² <i>Gifu University, Japan</i> , ³ <i>National Institute of Animal Health, Japan</i>
[P1.27]	Mutation in VP1 protein and emergence of novel Foot-and-Mouth Disease virus (FMDV) causing vaccination failure in Bangladesh M. Sultana, M.A. Hossain [*] , <i>University of Dhaka, Bangladesh</i>
[P1.28]	Inactivation of influenza A virus and RSV via low-energy electron irradiation provides a versatile method for efficacious vaccine production L. Bayer ^{*1} , J. Fertey ¹ , E. Hiller ² , S. Bailer ² , S. Rupp ² , A. Pohl ³ , C. Wetzel ³ , S. Ulbert ¹ , T. Grunwald ¹ , ¹ <i>Fraunhofer Institute for Cell Therapy and Immunology, Germany</i> , ² <i>Fraunhofer Institute for Interfacial Engineering and Biotechnology, Germany</i> , ³ <i>Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology, Dresden, Germany</i>
[P1.29]	Seroconversion and antibody levels of quadrivalent human papillomavirus vaccine in immunocompromised children: results of 5 years of follow-up study C.R. MacIntyre ^{1,6} , P. Shaw ² , F. Mackie ^{3,4} , C. Boros ⁵ , H. Marshall ⁵ , H. Seale ¹ , S. Kennedy ^{3,4} , A. Moa ¹ , A. Chughtai ^{*1} , E. O'Loughlin ² , A. Stormon ¹ , ¹ <i>University of New South Wales, Australia</i> , ² <i>Children's Hospital at Westmead, Australia</i> , ³ <i>Sydney Children's Hospital, Australia</i> , ⁴ <i>University of New South Wales, Australia</i> , ⁵ <i>The University of Adelaide, Australia</i> , ⁶ <i>Arizona State University, USA</i>
[P1.30]	The pig as an alternative animal model for <i>Chlamydia trachomatis</i> vaccine development A. Amaral ¹ , J.A. Pasternak ² , M. Delgado-Ortega ² , G. Hamonic ² , K. Lai ² , L. Lorenz ¹ , V. Gerdt ² , F. Meurens ^{2,3} , T. Kaeser ^{*1,2} , ¹ <i>North Carolina State University, USA</i> , ² <i>Vaccine and Infectious Disease Organization, Canada</i> , ³ <i>BIOEPAR, INRA, France</i>
[P1.31]	Adverse events after quadrivalent HPV vaccine notified to the adverse events following immunization information system (SI-EAPV) in Sao Paulo State, Brazil, 2014-2015 A.B. Mauro ¹ , E.G. Fernandes ² , K.T. Miyaji ^{*1} , B.A. Arantes ² , M.G. Valente ² , H.K. Sato ² , A.M.C. Sartori ¹ , ¹ <i>Hospital das Clinicas, Universidade de Sao Paulo, Brazil</i> , ² <i>Centro de Vigilancia Epidemiologica Prof. Alexandre Vranjac,</i>



11th Vaccine Congress

17-20 September 2017 • Paradise Point, San Diego, CA, USA



11th Vaccine Congress | Poster Program

	<i>Secretaria de Estado da Saude de Sao Paulo, Brazil</i>
[P1.32]	Low tetanus-diphtheria-acellular pertussis (Tdap) vaccine coverage among healthcare workers in a tertiary university hospital in Sao Paulo, Brazil: need for continuous surveillance and implementation of active strategies B.A. Randi, K.T. Miyaji*, A.N. Lara, K.Y. Ibrahim, V. Infante, M.H. Lopes, A.M.C. Sartori, <i>Universidade de Sao Paulo, Brazil</i>
[P1.33]	Stimulatory effects of heat-killed <i>Enterococcus faecalis</i> on cell-mediated immunity in fish Y. Matsuura* ^{1,2} , M. Takasaki ³ , R. Miyazawa ³ , T. Nakanishi ³ , ¹ <i>National Research Institute of Aquaculture, Fisheries Research and Education Agency, Japan</i> , ² <i>Research Fellow of Japan Society for the Promotion of Science, Japan</i> , ³ <i>Nihon University, Japan</i>
[P1.34]	Combination of asymmetrical flow field-flow fractionation and analytical ultracentrifugation is a powerful tool for size variant evaluation of inactivated poliovirus vaccine T. Torisu*, T. Satou, <i>Takeda Pharmaceutical Company Limited, Japan</i>
[P1.35]	Mucosal immunization of conserved sM2, HA2 of Influenza virus and cholera toxin subunit A1 (CTA1) fusion protein with PC nanoparticles induces protection against divergent influenza subtypes J-S. Lee*, M.Y. Chowdhury, C-J. Kim, <i>Chungnam National University, Republic of Korea</i>
[P1.36]	Inactivated Enterovirus 71 (EV71) Adjuvanted with PC Nanoparticles Induces High Cellular and Humoral Immune Responses in BALB/c Mice J-S. Lee*, P.S. Pathinayake, C-J. Kim, <i>Chungnam National University, Republic of Korea</i>
[P1.37]	Mucosal Immunization with <i>Lactobacillus</i>-displayed CTA1-conjugated influenza sM2HA2 induces Broad Protective Immune Responses against Divergent Influenza Subtypes J-S. Lee*, M.Y. Chowdhury, C-J. Kim, <i>Chungnam National University, Republic of Korea</i>
[P1.38]	Mucosal administration with recombinant <i>Lactobacillus</i>-displayed CTA1-conjugated PEDSe induces neutralizing immune responses against porcine epidemic diarrhea (PED) virus J-S. Lee*, C.Y. Hewawaduge, <i>Chungnam National University, Republic of Korea</i>
[P1.39]	Soluble Multi-VP1e antigen of FMDV emulsified with ISA 201 induces protection against lethal FMDV challenge J-S. Lee*, W-S. Goo, J-H. Kim, <i>Chungnam National University, Republic of Korea</i>

Posters Session II

Monday, 18 September 2017 at 18:00-19:30

[P2.01]	Mutation of EV71 VP1 determines the pathogenesis of Enterovirus 71 C.K. Chang* ^{1,2} , Y.H. Chow ^{1,3} , ¹ <i>National Health Research Institutes, Taiwan</i> , ² <i>National Defense Medical Center, Taiwan</i> , ³ <i>China Medical University, Taiwan</i>
[P2.02]	Adenovirus production in a single use stirred-tank bioreactor system A. Lagerlof*, G. Ahlén, T. Persson, S. Stier, M. Bennemo, M. Lundgren, <i>GE Healthcare, Sweden</i>
[P2.03]	Humoral immune response after immunisation with experimental subunit vaccines in pigs* A. Rzasa ¹ , O. Urbaniak ¹ , J. Bajzert ¹ , J. Miller ¹ , R. Kolodziejczyk ² , F. Jelen ² , S. Przybyl ³ , W. Jachymek ³ , C. Lugowski ³ , T. Stefaniak* ¹ , ¹ <i>Wroclaw University of Environmental and Life Sciences, Poland</i> , ² <i>Pure Biologics Ltd, Poland</i> , ³ <i>Institute of Immunology and Experimental Therapy, Poland</i>
[P2.04]	Mechanisms of antibody-mediated protection against Zika virus infection M.J. Bailey* ¹ , J. Duehr ¹ , J. Brown ¹ , M. Sourisseau ¹ , M. Evans ¹ , F. Krammer ¹ , V. Simon ¹ , J. Lim ¹ , P. Palese ¹ , G.S. Tan ^{1,2} , F. Broecker ¹ , ¹ <i>Icahn School of Medicine at Mount Sinai, USA</i> , ² <i>J. Craig Venter Institute, USA</i>
[P2.05]	Modified Vaccinia Lister, a safe and easy to produce vector for human or veterinary vaccines A. Ferrier-Rembert* ¹ , O. Ferraris ¹ , J. Dimier ¹ , A-L. Favier ¹ , P. Marianneau ³ , I. Schwartz ⁴ , T. Chrun ⁴ , D. Spohner ² , R. Drillien ² , C-N. Peyrefitte ¹ , ¹ <i>IRBA, France</i> , ² <i>IGBMC, France</i> , ³ <i>ANSES, France</i> , ⁴ <i>INRA, France</i>
[P2.06]	A baseline study of hospital policies for hepatitis B vaccination of healthcare workers in Botswana in 2012 S. Nunu ¹ , L. Fernandes ¹ , A. De Schryver ² , R.J. Burnett* ¹ , ¹ <i>Sefako Makgatho Health Sciences University, South Africa</i> , ² <i>University of Antwerp, Belgium</i>
[P2.07]	<i>Shigella flexneri</i> Y O-antigen delivered by attenuated <i>Salmonella enterica</i> Serovar Typhimurium induces cross-reactive immune responses against <i>Shigella flexneri</i> 2a in mice



11th Vaccine Congress

17-20 September 2017 • Paradise Point, San Diego, CA, USA



11th Vaccine Congress | Poster Program

	H. Su*, R. Curtiss, Q. Kong, <i>University of Florida, USA</i>
[P2.08]	Oral vaccine against group B Streptococcus: The first experimental approach D.A. Soto ¹ , Y.Y. Leyton ¹ , M.J. Altamirano ^{1,2} , D.A. Diaz-Dinamarca ^{1,2} , J.A. Soto ^{1,2} , A.M. Kalergis ² , A.E. Vasquez* ¹ , ¹ <i>Instituto de Salud Publica de Chile, Chile</i> , ² <i>P. Universidad Catolica de Chile, Chile</i>
[P2.09]	Effects of bone marrow-derived Mesenchymal stem cell treatment for group B streptococcus infection in animal model D.A. Soto* ¹ , D.P. Castillo ¹ , D.A. Diaz_Dinamarca ^{1,2} , P. Barrera ¹ , M.J. Altamirano ^{1,2} , F. Purcell ¹ , F. Carrion ³ , O. Lopez ⁴ , A.M. Kalergis ² , A.E. Vasquez ¹ , ¹ <i>Instituto de Salud Publica de Chile, Chile</i> , ² <i>P. Universidad Catolica de Chile, Chile</i> , ³ <i>Universidad del Desarrollo, Chile</i> , ⁴ <i>Universidad Santo Tomas, Chile</i>
[P2.10]	Politics of vaccines in Texas and the public health policy implications R. Lakshmanan* ¹ , J. Suh ² , C.J. Rohr-Allegri ¹ , ¹ <i>The Immunization Partnership, USA</i> , ² <i>Immunize Texas, USA</i>
[P2.11]	Optimizing VacSIM® delivery of malaria CeTOS and CSP antigens to enhance vaccine efficacy L.M. Shollenberger* ¹ , J.V. Dixon ¹ , E. Angov ² , D.A. Harn ¹ , ¹ <i>University of Georgia, USA</i> , ² <i>Walter Reed Army Institute for Research, USA</i>
[P2.12]	Immunogenicity and safety of hepatitis B injection in the dermis in healthy volunteers using an intradermal injection device (VAX-ID) T.J.S. Van Mulder* ^{1,2} , K. Withanage ² , M. de Koeijer ¹ , L. Ruggiero ¹ , K.C.L. Beyers ¹ , V. Vankerckhoven ^{1,2} , P. Van Damme ² , ¹ <i>Novosanis nv, Belgium</i> , ² <i>University of Antwerp, Belgium</i>
[P2.13]	Novel pneumocystis surface protein as vaccines to prevent infection S. Ruan* ¹ , Y. Cai ² , D. Welsh ¹ , A.J. Ramsay ¹ , J.E. Shellito ¹ , ¹ <i>LSU Health Sciences Center, USA</i> , ² <i>University of New Orleans, USA</i>
[P2.16]	Influenza virus hemagglutinin-specific antibodies in human sera measured by ELISA correlate with in vivo protection in a mouse serum transfer model H. Jacobsen ^{1,2} , M. Rajendran ¹ , A. Choi ¹ , H. Sjurksen ³ , K.A. Brokstad ³ , R.J. Cox ³ , P. Palese ¹ , F. Krammer ¹ , R. Nachbagauer* ¹ , ¹ <i>Icahn School of Medicine at Mount Sinai, USA</i> , ² <i>Heinrich Pette Institute, Germany</i> , ³ <i>University of Bergen, Norway</i>
[P2.17]	The efficacy of adjuvant with vaccine against avian influenza H7N9 J. Heo, K.B. Park, H.S. Park, Y.S. Kim*, <i>Vaccine R&D team, Central Institute, IL-YANG Pharm. Co., Ltd., Republic of Korea</i>
[P2.18]	Prevalence of rotavirus infection among vaccinated and non vaccinated children aged 1-5 years in Saudi Arabia with the focus on associated side effects and complications of rota virus vaccination E. Paul* ¹ , I. Alzaydani ² , A. El-Mekki ¹ , A. Hakami ¹ , H. Chandramoorthy ¹ , A. Hawan ³ , ¹ <i>King Khalid University. Ministry of Higher Education, Saudi Arabia</i> , ² <i>Abha Maternity and Children hospital. Ministry of Health, Saudi Arabia</i> , ³ <i>Armed forces hospital Southern region, Saudi Arabia</i>
[P2.19]	Identification of albumin-binding domain-derived protein replicas of HIV-neutralizing antibodies paratopes as a novel tools for the induction of broadly neutralizing antibodies against HIV-1 gp120 glycoprotein M. Raska* ^{1,3} , M. Kuchar ² , L. Barkoczi ¹ , P. Kosztyu ¹ , J. Turanek ³ , P. Maly ² , ¹ <i>Palacky University Olomouc, Czech Republic</i> , ² <i>Institute of Biotechnology CAS, Czech Republic</i> , ³ <i>Veterinary Research Institute, Czech Republic</i>
[P2.20]	Study of deglycosylated chimeric porcine reproductive and respiratory syndrome virus as a vaccine candidate and its economic benefit at commercial pig farm level K.H. Cho* ¹ , J.J. Kim ² , J.A. Lee ³ , J.H. Han ⁵ , W. Hur ⁶ , J.H. Pi ⁷ , J.K. Lee ⁸ , S. Park ⁹ , W. Jeong ¹ , J.B. Lee ⁴ , ¹ <i>Animal and Plant Quarantine Agency, Republic of Korea</i> , ² <i>Ministry of Agriculture, Food and Rural Affairs, Republic of Korea</i> , ³ <i>Korea Center for Disease Control and Prevention, Republic of Korea</i> , ⁴ <i>Konkuk University, Republic of Korea</i> , ⁵ <i>KBNP, INC., Republic of Korea</i> , ⁶ <i>Daesung Microbiological Labs. Co., LTD., Republic of Korea</i> , ⁷ <i>Sungwoo Agricultural Co., Republic of Korea</i> , ⁸ <i>Midwestern University, USA</i> , ⁹ <i>Brown University, USA</i>
[P2.21]	Statistics trend : Vaccine adverse event reports of pediatrics in Korea S. Chung*, Y. Woo, M. Kim, B. Kim, <i>korea Institute of Drug Safety and Risk Management, Republic of Korea</i>
[P2.22]	Vaccine adverse drug reaction management and relief system in Korea Y. Jang*, E. Noh, S. Shin, J. Park, G. Lee, S. Chung, <i>Korea Institute of Drug Safety and Risk Management, Republic of Korea</i>
[P2.23]	Expression of recombinant lysozyme-PMAP36 fusion protein and protection efficacy of the fusion protein-inactivated Salmonella Typhimurium vaccine in a murine model J.Y. Moon ¹ , W.K. Kim ¹ , S.S. Han ² , D.S. Tark ² , J. Hur* ¹ , ¹ <i>Chonbuk National University, Republic of Korea</i> , ² <i>Chonbuk</i>



11th Vaccine Congress

17-20 September 2017 • Paradise Point, San Diego, CA, USA



11th Vaccine Congress | Poster Program

	<i>National University Korea Zoonosis Research Institute, Republic of Korea</i>
[P2.24]	The public health Impact of a herpes zoster vaccination program in Canada, Following the current Ontario recommendation D.A.M. van Oorschot* ¹ , A. McGirr ² , R. Widenmaier ² , L. Varghese ³ , D. Curran ¹ , ¹ GSK, Belgium, ² GSK, Canada, ³ GSK, Singapore
[P2.25]	Press-stroke treatment of the skin is a physical adjuvant to intradermal vaccination J. Zhang, T.T. Chen, N.H. Liu, J.X. Liu, Z. Ding*, <i>Nanjing University, China</i>
[P2.26]	One shot Nipah virus like particles (NiV VLPs) vaccine protect in the hamster model P. Walpita* ¹ , Y. Cong ² , P. Jahrling ² , O. Rojas ² , E. Pastnikova ² , S. Yu ² , L. Johns ¹ , M.R. Holbrook ² , ¹ University of Hawaii, USA, ² National Institute of Allergy and Infectious Diseases, USA
[P2.27]	A novel vaccinia-based multi-disease vaccine against chikungunya and Zika viruses N.A. Prow ¹ , L. Liu ² , P. Eldi ² , T.H. Cooper ² , B. Tang ¹ , A.A. Khromykh ³ , K.R. Diener ² , P.M. Howley ⁴ , J.D. Hayball ² , A. Suhrbier* ¹ , ¹ QIMR Berghofer Medical Research Institute, Australia, ² Hanson Institute and Sansom Institute, Australia, ³ The University of Queensland, Australia, ⁴ Sementis Ltd, Australia
[P2.28]	Uncovering the mode-of-action of novel lipid nanoparticle based vaccine formulations G. Swaminathan*, S. Lin, M. Patel, K. DiFelice, J. Smith, M. Gindy, A. Mahne, D. Cua, A. Espeseth, A. Bett, <i>Merck Research Laboratories, USA</i>
[P2.29]	Stochastic optimization of vaccine vial replenishment: A case study in Bangladesh Z. Azadi ¹ , H. Gangammanavar ² , S. Eksioğlu* ¹ , ¹ Clemson university, USA, ² Southern Methodist University, USA
[P2.30]	PBS-12SF cells: An alternative continuous cell line for human and veterinary vaccine production P.M. Coussens, <i>Michigan State University, USA</i>
[P2.31]	Brucella lipopolysaccharide reinforced Salmonella delivering Brucella immunogens protects mice against virulent challenge J.H. Lee, <i>Chonbuk National University, College of Veterinary Medicine, Republic of Korea</i>
[P2.32]	Competition of adenovirus epitopes with transgene epitopes - investigation of particular mechanisms of immunosuppression in adenovirus-based immunization C.P. Hrycak*, D. Schöne, U. Dittmer, W. Bayer, <i>University Hospital Essen, Germany</i>
[P2.33]	Flagellin is a Th1 polarizing adjuvant for human T cells and induces protection in a murine neonatal vaccination model for rotavirus infection R-G. Labastida* ¹ , O. Ramirez ¹ , M. Peleteiro ² , M-E. Garet ² , D-V. Lopez ¹ , O-D. Badillo ¹ , M-L. Gutiérrez ³ , A. González ² , F-R. Esquivel ¹ , M-A. Santana ¹ , ¹ Universidad Autónoma de Estado de Morelos, Mexico, ² Universidad de Vigo, Spain, ³ Instituto Nacional de Salud Publica, Mexico
[P2.34]	Mice lacking IgA exhibit defective IgG responses to polysaccharide antigens Y. Furuya*, D.W. Metzger, <i>Albany Medical College, USA</i>
[P2.35]	Hepatitis A vaccine non-response after two doses A.N. Lara, K.T. Miyaji*, A.M. Sartori, K.Y. Ibrahim, A.L. Galastri, B. Ignoto, I.C. Costa, M.H. Lopes, <i>Universidade de São Paulo, Brazil</i>
[P2.36]	Generation and characterization of a stable cell population releasing multivalent Epstein-Barr virus-like particles that function as a potential prophylactic vaccine J. Foley, L. Mutsunguma, P. Ye, J.G. Ogembo*, <i>Beckman Research Institute of City of Hope, USA</i>
[P2.37]	Assessment of K3-SPG, nano-particulate CpG DNA, as an immunotherapeutic agent in non-human primate models <i>in vivo</i> Y. Masuta* ^{1,3} , T. Yamamoto ^{1,2} , K. Ishii ^{1,2} , ¹ National Institutes of Biomedical Innovation, Health and Nutrition, Japan, ² Osaka University, Japan, ³ Nippon Shinyaku Co., Ltd, Japan
[P2.38]	Local transmission of classical Swine Fever vaccine strain (LOM) in Jeju island in South Korea W. Jeong*, S.D. PARK, Y.M. Kang, J.H. Kim, H. Yoon, K.H. Cho, K. Lee, H.S. Park, <i>Animal & Plant Quarantine Agency, Republic of Korea</i>
[P2.39]	Bacillus cereus Tor16585: an alternate source of capsule for anthrax vaccines and virulence studies D.J. Chabot* ¹ , W.R. Ribot ¹ , T.A. Timothy ¹ , J.T. Ladner ¹ , J. Chua ¹ , S.S. Ingavale ¹ , A.R. Woolfitt ² , J.R. Barr ² , A.E. Boyer ² , A.M. Friedlander ¹ ¹ US Army Medical Research Institute of Infectious Diseases, USA, ² Centers for Disease Control and Prevention, USA



11th Vaccine Congress

17-20 September 2017 • Paradise Point, San Diego, CA, USA



11th Vaccine Congress | Poster Program